Business Context and Reporting Period
Company: Boston Scientific Corporation
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 1998
Industry: Minimally Invasive Medical Devices
Boston Scientific is a global developer, manufacturer, and marketer of medical devices used in cardiology, electrophysiology, gastroenterology, neuro-endovascular therapy, and other specialties. The company's strategy focuses on product diversity, innovation, and strategic acquisitions to achieve "strategic mass" in the healthcare market. In 1998, the company completed two major acquisitions: CardioGene Therapeutics, Inc. (gene therapy) and Schneider Worldwide (a pioneer in less invasive medicine formerly part of Pfizer).
Key Financial Metrics
Revenue: Net sales for 1998 were $2.2 billion, a substantial increase from $1.8 million in 1979. Approximately 80% of sales were derived from the vascular business, 19% from nonvascular, and 1% from other businesses. International sales accounted for approximately 38% of net sales.
Research & Development: The company expended $200 million on R&D in 1998, representing approximately 9% of net sales.
Market Capitalization: As of March 15, 1999, the aggregate market value of common stock held by non-affiliates was approximately $9.2 billion. The closing stock price on that date was $33.75.
Employees: As of December 31, 1998, the company employed nearly 14,000 people globally, with approximately 4,000 in international operations.
Debt and Liquidity: The filing text does not provide specific values for total debt, cash flow, or liquidity ratios. However, the company references a "Second Amended and Restated Credit Agreement" dated September 4, 1998, and the issuance of $500 million in 6.625% Promissory Notes due March 15, 2005.
Allowances: The allowance for uncollectible amounts and sales returns increased from $30.5 million at the beginning of 1998 to $49.2 million at year-end.
Material Changes and Operational Highlights
- Acquisitions: The acquisition of Schneider Worldwide significantly increased the company's size and complexity. Management expects to complete the integration of Schneider by the end of 1999.
- Leadership Transition: On March 18, 1999, James R. Tobin was appointed President and Chief Executive Officer. Pete M. Nicholas continued as Chairman of the Board.
- Workforce Rationalization: Following the Schneider acquisition, the company initiated a rationalization plan expected to displace approximately 2,000 positions in 1999 (over half in manufacturing), while adding approximately 1,000 new positions.
- Stock Split: A 2-for-1 common stock split was effected on November 30, 1998, following a shareholder vote to increase authorized shares.
- Supply Chain Optimization: A global program was initiated in 1998 to lower inventory levels, reduce manufacturing costs, and improve gross margins, with full implementation expected by the end of 1999.
Outlook, Risks, and Contingencies
Management Outlook: Management believes the company is well-positioned to take advantage of growth opportunities despite a challenging healthcare environment characterized by cost containment and managed care. The company does not expect significant acquisitions in 1999 but will continue to review strategic opportunities.
Key Risks:
- Integration Risk: Failure to effectively integrate recent acquisitions could adversely affect operating results and strategic objectives.
- Reimbursement and Pricing Pressure: Increased pressure from managed care, large buying groups, and hospital consolidations may compress gross margins and impact selling prices.
- Regulatory and Legal: The company faces significant competition and potential patent litigation. Notable proceedings include a suit by Medtronic AVE Inc. regarding balloon dilation catheters in Europe and a suit by Cook, Inc. regarding the Radius coronary stent in the U.S.
- Foreign Currency: With 38% of sales international, the company is exposed to foreign currency fluctuations which may impact margins.
- Product Liability: Inherent risks exist regarding product liability claims, though management believes current insurance coverage is adequate.
Investor Verification Checklist
- Verify the specific financial impact of the Schneider Worldwide acquisition on 1998 net income and cash flow, as detailed figures are incorporated by reference in the Annual Report to Shareholders.
- Monitor the progress of the integration of Schneider Worldwide and the execution of the workforce rationalization plan (2,000 displacements vs. 1,000 additions).
- Track the status of pending patent litigation with Medtronic AVE Inc. and Cook, Inc., as adverse outcomes could result in significant liabilities or injunctions.
- Assess the effectiveness of the supply chain optimization program in restoring gross margins to "acceptable levels" by the end of 1999.
- Review the company's exposure to foreign currency fluctuations given the 38% international sales mix and the effectiveness of hedging strategies.
- Confirm the regulatory approval status of key pipeline products, such as the NIR ON VIVA! stent and the NIR ON Ranger with SOX delivery system, scheduled for potential U.S. introduction in 1999.